SCHEMBL13640661

SCHEMBL13640661

CC(=O)c1cc(NC(=O)c2c(F)cccc2F)ccc1-c1cc(-c2cccnc2)sc1C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.47
▸ DYRK1A Q13627 3/20 0.42
▸ DYRK1B Q9Y463 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ BRAF P15056 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NOD2 Q9HC29 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CSF1R P07333 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ MAPK7 Q13164 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ IL2 P60568 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13321607 0.92 LMNA (0.45) LMNADYRK1ADYRK1BMAPTBRAF
SCHEMBL7928883 0.86 LMNA (0.47) LMNADYRK1ADYRK1BMAPTBRAF
SCHEMBL13321606 0.78 LMNA (0.45) LMNADYRK1ADYRK1BMAPTBRAF
SCHEMBL2894859 0.77 LMNA (0.55) LMNADYRK1ADYRK1BMAPTJAK2
SCHEMBL2315507 0.76 LMNA (0.56) LMNADYRK1ADYRK1BMAPTJAK2
SCHEMBL2315252 0.76 LMNA (0.51) LMNADYRK1ADYRK1BMAPTJAK2
SCHEMBL7917075 0.75 LMNA (0.52) LMNADYRK1ADYRK1BMAPTJAK2
SCHEMBL2315494 0.75 LMNA (0.52) LMNADYRK1ADYRK1BMAPTJAK2
SCHEMBL2886943 0.73 LMNA (0.55) LMNADYRK1ADYRK1BMAPTBRAF
SCHEMBL2311767 0.69 IL2 (0.47) LMNADYRK1ADYRK1BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165451-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2013-06-27 — — US disclosed
US-20120283272-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2012-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283272-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR1, CCR8 LMNA 4757/4885DYRK1A 4239/4885DYRK1B 4410/4885
US-20130165451-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR1, CCR8 LMNA 4757/4885DYRK1A 4239/4885DYRK1B 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback